The Iniciativa Profilaxis Pre-Exposicin ( iPrEx ) study randomly assigned @ HIV-seronegative men and transgender women who have sex with men ( MSM ) to receive oral daily TDF coformulated with emtricitabine ( FTC/TDF ) or placebo .